BLOCKCHAIN IN PHARMA
Get instant access to latest e-book

latest newsRead more...

22

Mar 2019

Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule

Alexion Pharmaceuticals Inc and Affibody AB today announced a partnership to codevelop ABY for rare Immunoglobulin G IgGmediated autoimmune diseases Currently in Phase development ABY is a bivalent antibodymimetic that targets the neonatal Fc receptor FcRn ABY has been specifically designed to combine Affibodys protein…

22

Mar 2019

Biologics by McKesson Expands Specialty Pharmacy Capabilities to Serve Patients with Rare and Complex Conditions

Biologics by McKesson continues to expand its capabilities as a specialty pharmacy expert in oncology and complex conditions through a new exclusive distribution agreement After making recent investments to leverage more than years of oncology experience into other complex conditions Biologics has been selected by…

21

Mar 2019

Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics

Vivet Therapeutics a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need and Pfizer Inc NYSE PFE announced today that Pfizer has acquired a equity interest in Vivet and secured an exclusive option…

21

Mar 2019

Takeda and HemoShear Therapeutics Extend Exclusive Drug Discovery Partnership in Liver Diseases

HemoShear Therapeutics LLC a privately held biotechnology company today announced an extension of its partnership with Takeda Pharmaceutical Company Limited to discover and develop additional novel therapeutics for liver diseases including nonalcoholic steatohepatitis NASH We are excited that Takeda recognizes our unique ability to identify…

press releasesRead more...

22

Mar 2019

Lead Pharma Announces Start of Phase I Clinical Trials with SAR441169 Candidate Treatment for Psoriasis

Lead Pharma a pharmaceutical company developing innovative medicines for the treatment of immunological and oncological indications today announced that it has achieved a fourth milestone under its license collaboration agreement…

22

Mar 2019

Knopp Biosciences Collaborates with Leading British Researchers to Initiate Phase II Clinical Trial of Dexpramipexole in the Treatment of Severe Eosinophilic Asthma

Knopp Biosciences LLC a private drug discovery and development company dedicated to providing breakthrough treatments for inflammatory and neurological diseases with high unmet medical needs announced today a collaboration with…

22

Mar 2019

Primex Pharmaceuticals and Nordic Group Sign a Strategic Partnership to Commercialise OZALIN® in France

Nordic Group a pharmaceutical company focusing on the development and commercialisation of hospital and orphan products and Primex Pharmaceuticals AG an innovative global Anaesthesia pharmaceutical company announced a strategic agreement…

22

Mar 2019

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease

Biogen and Eisai Co Ltd announced the decision to discontinue the global Phase trials ENGAGE and EMERGE designed to evaluate the efficacy and safety of aducanumab in patients with mild…

22

Mar 2019

AlzProtect Starts Collaboration with PAREXEL Biotech for Phase 2a of AZP2006 for the Treatment of Progressive Supranuclear Palsy (PSP)

ALZPROTECT a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimers disease today announced that PAREXEL Biotech a new division of PAREXEL International Corporation has been…

EventsRead more...

24-27

Mar 2019

15th Annual Pharma Forum 2019

CBI
New York Marriott Marquis

25-26

Mar 2019

19th Annual Medicinal & Pharmaceutical Sciences Congress

Conference Series LLC Ltd
Courtyard by Marriott Hong Kong

25-26

Mar 2019

3rd Product Complaints Forum

ExL Events, Inc.
The Inn at Penn, a Hilton Hotel

25-26

Mar 2019

Medical Device Safety & Reporting Summit

ExL Events, Inc.
The Inn at Penn, a Hilton Hotel

TOP ARTICLES

  • 4

    Are you Ready for EU FMD?

    With the deadline looming for enactment of EU FMD and US DSCSA Vikash Pushpraj Senior Vice President rfxcel explains how achieving compliance is about much more..
  • 6

    Cancer Stem Cell (CSC) Inhibitors

    Cancer as a group of heterogeneous diseases very well known Unimaginable amounts of money and manhours have been spent in finding cure for this deadly disease H..

Knowledge Bank

  • Interviews

    Merck

    Staff Engineer, Manufacturing Science and Technology, South East Asia
    Karen Chan is a process engineer at Merck Pte Ltd Chan has six years of experience in the biopharmaceutical industry and two years of experience in research development She provides technical support in areas such as process development troubleshoot..

  • Articles

    Nanomedicines management for advance therapy of NeuroAIDS: State of art

    Introduction The Human Immune deficiency Virus HIV infected brain cells through virus or HIV linked oncogenes The major complication of such infection leads to dementia peripheral neuropathies neurosyphilis meningitis etc The development of neuroAIDS still remains a topic of debate due to multifaceted symptom complicated pathology along with lack of precise diagnostic protocol or…

Editorial Section

  • Strategy

    WAYS TO CREATE MORE AND MORE CONSISTENT PERFORMERS

    For all pharma businesses it is a challenge to enable their field forceSales and Marketingto be consistent performers The success or failure in this direction will accordingly decide the fate of the organisations Even if an organisation has highly innovative…

  • Research development

    New and Novel Drug Delivery Technologies

    By infusing drugs with new and innovative therapeutic benefits drug delivery systems extend products profitable lifecycle giving pharmaceutical companies competitive and financial advantages and providing patients with improved medications Formulation development is being used in the creation of new dosage…

  • Clinical Trials

    ELIXIR FOR SOURCING AND RETAINING CANDIDATES

    Many pharma companies have been suffering silently from shortage of suitable candidates to fill up vacancies in the field and also of high attrition rate leading to terrible but avoidable loss of business due to vacancies In this article lets…

TOP